Abstract
Mathematical models have been widely used during the ongoing SARS-CoV-2 pandemic for data interpretation, forecasting, and policy making. However, most models are based on officially reported case numbers, which depend on test availability and test strategies. The time dependence of these factors renders interpretation difficult and might even result in estimation biases.
Here, we present a computational modelling framework that allows for the integration of reported case numbers with seroprevalence estimates obtained from representative population cohorts. To account for the time dependence of infection and testing rates, we embed flexible splines in an epidemiological model. The parameters of these splines are estimated, along with the other parameters, from the available data using a Bayesian approach.
The application of this approach to the official case numbers reported for Munich (Germany) and the seroprevalence reported by the prospective COVID-19 Cohort Munich (KoCo19) provides first estimates for the time dependence of the under-reporting factor. Furthermore, we estimate how the effectiveness of non-pharmaceutical interventions and of the testing strategy evolves over time. Overall, our results show that the integration of temporally highly resolved and representative data is beneficial for accurate epidemiological analyses.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Bavarian State Ministry of Science and the Arts, the University Hospital of Ludwig-Maximilians-University Munich, the Helmholtz Centre Munich, the University of Bonn (via the Transdiciplinary Research Areas), the University of Bielefeld, Munich Center of Health (McHealth) and the German Ministry for Education and Research (MoKoCo19, reference number 01KI20271), German Research Foundation (SEPAN, reference number HA7376/3-1), Volkswagen Stiftung (reference number: 99 450). This work was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy EXC 2047/1 - 390685813 and EXC 2151 - 390873048. The ORCHESTRA project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101016167. The views expressed in this paper are the sole responsibility of the authors and the Commission is not responsible for any use that may be made of the information it contains. The funders had no role in study design, data collection, data analyses, data interpretation, writing, or submission of this manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the Institutional Review Board at the Ludwig-Maximilians-University in Munich, Germany (opinion date 31 March 2020, number 20-275, opinion date amendment: 10 October 2020), prior to study initiation.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
New simulations data with improved prior distribution (qualitative results are unchanged). Materials and Methods section has been enlarged to include more details about the modelling. Additional figures both in text and supplement have been added. Additional supplement with full model equations has been added.
Data Availability
The data used in this manuscript (except data from public sources such as the Robert Koch Institute) cannot be made public due to patient consent.
